[go: up one dir, main page]

PL3021838T3 - Leczenie otyłości - Google Patents

Leczenie otyłości

Info

Publication number
PL3021838T3
PL3021838T3 PL14825724T PL14825724T PL3021838T3 PL 3021838 T3 PL3021838 T3 PL 3021838T3 PL 14825724 T PL14825724 T PL 14825724T PL 14825724 T PL14825724 T PL 14825724T PL 3021838 T3 PL3021838 T3 PL 3021838T3
Authority
PL
Poland
Prior art keywords
obesity
treatment
Prior art date
Application number
PL14825724T
Other languages
English (en)
Inventor
Moise A. Khayrallah
Gary Bream
Stephen E. Butts
Original Assignee
Jazz Pharmaceuticals Ireland Limited
Sk Biopharmaceuticals Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jazz Pharmaceuticals Ireland Limited, Sk Biopharmaceuticals Co., Ltd filed Critical Jazz Pharmaceuticals Ireland Limited
Publication of PL3021838T3 publication Critical patent/PL3021838T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL14825724T 2013-07-18 2014-07-18 Leczenie otyłości PL3021838T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361847593P 2013-07-18 2013-07-18
PCT/US2014/047186 WO2015010014A1 (en) 2013-07-18 2014-07-18 Treatment for obesity
EP14825724.9A EP3021838B1 (en) 2013-07-18 2014-07-18 Treatment for obesity

Publications (1)

Publication Number Publication Date
PL3021838T3 true PL3021838T3 (pl) 2021-03-08

Family

ID=52344067

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14825724T PL3021838T3 (pl) 2013-07-18 2014-07-18 Leczenie otyłości

Country Status (12)

Country Link
US (6) US9226910B2 (pl)
EP (1) EP3021838B1 (pl)
JP (2) JP6529495B2 (pl)
KR (1) KR102309836B1 (pl)
CN (2) CN105873576B (pl)
CA (1) CA2917702A1 (pl)
DK (1) DK3021838T3 (pl)
ES (1) ES2812586T3 (pl)
PL (1) PL3021838T3 (pl)
PT (1) PT3021838T (pl)
TW (1) TW201919605A (pl)
WO (1) WO2015010014A1 (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6529495B2 (ja) * 2013-07-18 2019-06-12 ジャズ ファーマスティカルズ インターナショナル スリー リミテッドJazz Pharmaceuticals International Iii Limited 肥満の治療
TWI655179B (zh) * 2014-02-28 2019-04-01 南韓商愛思開生物製藥股份有限公司 胺基羰基胺基甲酸酯化合物
WO2016141103A1 (en) * 2015-03-02 2016-09-09 Funfare, Llc Three dimensional printer and cartridge
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
EP3509582B1 (en) 2016-09-06 2023-12-20 Axsome Malta Ltd. Solvate form of (r)-2-amino-3-phenylpropyl carbamate
US10195151B2 (en) * 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
EP3523275B1 (en) * 2016-10-06 2023-09-27 Axsome Malta Ltd. Carbamoyl phenylalaninol compounds for medical use
JP2020528075A (ja) 2017-06-02 2020-09-17 ジャズ ファーマシューティカルズ アイルランド リミテッド 過度の眠気を処置するための方法および組成物
EP3661911A4 (en) 2017-07-31 2021-04-14 Jazz Pharmaceuticals Ireland Limited CARBAMOYL-PHENYLALANINOL ANALOGS AND USES THEREOF
US11400065B2 (en) 2019-03-01 2022-08-02 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
EP4033068A1 (en) 2021-01-25 2022-07-27 Welltec A/S Downhole wireline tool string
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
WO2025006965A1 (en) 2023-06-29 2025-01-02 Axsome Therapeutics, Inc. Methods of administering solriamfetol to lactating women

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA943862B (en) 1993-06-10 1995-12-04 Lilly Co Eli Method of preventing emesis and treating sexual dysfunction using tetrahydrobenz[cd] indole-6-carboxamides
KR100197892B1 (ko) 1994-09-09 1999-06-15 남창우 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법
KR0173862B1 (ko) 1995-02-11 1999-04-01 조규향 O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
US5756817C1 (en) 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
KR0173863B1 (ko) 1995-04-10 1999-04-01 조규향 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
JP4068154B2 (ja) 1996-10-10 2008-03-26 エス ケー コーポレイション O―カルバモイル―フェニルアラニノール化合物とその薬剤学的に有用な塩及びその製造方法
AU4674797A (en) 1996-10-22 1998-05-15 Ortho Pharmaceutical Corporation Phenylalaninol derivatives for the treatment of central nervous system disorders
DE10148233A1 (de) * 2001-09-28 2003-04-10 Boehringer Ingelheim Pharma Verbindungen zur Reduzierung übermäßiger Nahrungsaufnahme
US20040029941A1 (en) * 2002-05-06 2004-02-12 Jennings Julianne E. Zonisamide use in obesity and eating disorders
TW200507850A (en) * 2003-07-25 2005-03-01 Kyowa Hakko Kogyo Kk Pharmaceutical composition
US20050080268A1 (en) 2003-10-08 2005-04-14 Yong-Moon Choi Process of preparing O-carbamoyl compounds in the presence of active amine group
KR20070083826A (ko) 2004-10-28 2007-08-24 에스케이 주식회사 우울증을 위한 부가 요법
JP5024635B2 (ja) * 2005-06-08 2012-09-12 エスケー バイオファーマスティカルズ カンパニー リミテッド 睡眠覚醒障害の治療
ATE459393T1 (de) 2005-06-22 2010-03-15 Sk Holdings Co Ltd Behandlung der sexuellen dysfunktion
WO2007018496A1 (en) 2005-07-26 2007-02-15 Janssen Pharmaceutica, N.V. Methods for treating substance-related disorders
CN101557804A (zh) 2006-10-13 2009-10-14 詹森药业有限公司 氨基甲酸苯基烷基氨基酯组合物
CA2622696A1 (en) * 2007-11-05 2009-05-05 Diane Mcintosh Methods and compositions for retarding weight gain associated with use of atypical antipsychotic drugs
WO2009129181A1 (en) * 2008-04-14 2009-10-22 Concert Pharmaceuticals Inc. Propanediol-dicarbamate derivatives
US8741950B2 (en) * 2009-06-22 2014-06-03 Sk Biopharmaceuticals Co., Ltd. Methods for treating or preventing fatigue
US8232315B2 (en) * 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
ES2447295T3 (es) 2009-11-06 2014-03-11 Sk Biopharmaceuticals Co., Ltd. Métodos para el tratamiento del trastorno de déficit de atención/hiperactividad
RU2557533C2 (ru) 2009-11-06 2015-07-20 Ск Биофармасъютиклс Ко., Лтд. Способы лечения синдрома фибромиалгии
JP5761173B2 (ja) * 2010-03-04 2015-08-12 味の素株式会社 糖尿病又は肥満症の予防又は治療剤
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
ES2927675T3 (es) 2013-03-13 2022-11-10 Jazz Pharmaceuticals Ireland Ltd Tratamiento de la cataplexia
JP6529495B2 (ja) * 2013-07-18 2019-06-12 ジャズ ファーマスティカルズ インターナショナル スリー リミテッドJazz Pharmaceuticals International Iii Limited 肥満の治療

Also Published As

Publication number Publication date
WO2015010014A1 (en) 2015-01-22
US10105341B2 (en) 2018-10-23
US20190099395A1 (en) 2019-04-04
ES2812586T3 (es) 2021-03-17
US11497725B2 (en) 2022-11-15
CN110638804A (zh) 2020-01-03
US12201601B2 (en) 2025-01-21
US20230172896A1 (en) 2023-06-08
US9226910B2 (en) 2016-01-05
JP6529495B2 (ja) 2019-06-12
EP3021838A1 (en) 2016-05-25
US20170340596A1 (en) 2017-11-30
JP2016532679A (ja) 2016-10-20
JP2019089859A (ja) 2019-06-13
CA2917702A1 (en) 2015-01-22
US20160081970A1 (en) 2016-03-24
DK3021838T3 (da) 2020-08-24
CN105873576A (zh) 2016-08-17
EP3021838A4 (en) 2017-01-18
US9649291B2 (en) 2017-05-16
KR20160032127A (ko) 2016-03-23
JP6824315B2 (ja) 2021-02-03
CN105873576B (zh) 2019-07-19
PT3021838T (pt) 2020-09-01
US20150025136A1 (en) 2015-01-22
TW201919605A (zh) 2019-06-01
US20210077450A1 (en) 2021-03-18
KR102309836B1 (ko) 2021-10-12
EP3021838B1 (en) 2020-05-27

Similar Documents

Publication Publication Date Title
PL3021838T3 (pl) Leczenie otyłości
IL244869A0 (en) Device treatment
HK1220104A1 (zh) 用於醫治肥胖的胃內裝置
GB201302789D0 (en) Apparatus
GB201300928D0 (en) Apparatus
GB2512025B (en) Surface treatment device
HK1215164A1 (zh) 處理方法
GB201304872D0 (en) Treatment
GB201308440D0 (en) Therapeutic
IL245463A0 (en) valve
GB201310755D0 (en) Therapy
GB2509800B (en) Splint
GB201318668D0 (en) Sonosensitive therapeutic
GB201312419D0 (en) Manipulation treatment apparatus
GB201307310D0 (en) Treatment
GB201316521D0 (en) Therapeutic apparatus
GB201311738D0 (en) Apparatus
GB201310529D0 (en) Traysealing apparatus
GB2509801B (en) Splint
GB201304811D0 (en) Novel treatment for hypertension
GB201321115D0 (en) Treatment
GB201309238D0 (en) Treatment
PH22013000280U1 (en) Splint
GB201310661D0 (en) Splint
GB201322764D0 (en) Treating places